Cymbalta,Abilify,Nexium and Combivent are huge. Crestor, Namenda,Celebrex,Restasis,Crestor and Lidoderm should be important also. Procrit I'm not sure about as it's more institutional than community. Seroquel XR is difficult to judge as the immediate release form is already generic and the XR has just been so-so. The XR could however get significant numbers of switch from immediate release form as physicians tend to like the improved compliance of XR. Depends somewhat on insurance co. acceptance. Diovan, Excelon,Travatan Z, Zyvox, Aggenox and Copaxone won't mean a lot but every little bit helps. We will only see 6-12 months of significant results from these as margins shrink rapidly after that. I would not expect these to necessarily improve the pharmacy margins of the past few quarters as these just replace some other patent expirations which are losing their impact. 2014 may be the last true "windfall" year as expirations are much less significant after that.